Ensartinib vs standard chemotherapy after lung surgery for ALK-positive cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial compares ensartinib with standard platinum-based chemotherapy as “adjuvant” treatment—medicine given after surgery to lower the chance the cancer comes back. It’s for people with stage IIA to IIIA ALK-positive non-small cell lung cancer who had their tumor surgically removed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You had surgery to remove stage IIA to IIIA non-small cell lung cancer, and pathology shows ALK-positive disease
- Your surgery must have had clear margins (no cancer at the cut edges) and be done within 10 weeks before starting the study drug
- You must have a good daily functioning level (ECOG score 0 or 1)
- You need to be able to swallow and absorb study medicine well enough, and have adequate organ function (kidneys/liver/blood counts)
- Any big surgery must be finished at least 4 weeks before starting, and minor procedures at least 2 weeks before starting
- You agree to follow the study plan and sign informed consent
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether taking ensartinib (a targeted pill) after lung cancer surgery can lower the chance the cancer comes back. It is for people with ALK-positive non-small cell lung cancer (NSCLC) whose cancer has been fully removed and who have recovered from treatment.
This Phase 3 trial tests whether ensartinib given after surgery can lower the risk of lung cancer coming back in people with ALK-positive non-small cell lung cancer. You may be eligible if your tumor was completely removed and your recovery and lab tests meet specific requirements.
This trial tests whether taking ensartinib before surgery can help people with a specific type of lung cancer that has the ALK gene change. It is for those whose cancer is stage II or III and can be surgically removed.
This trial tests different treatments after surgery for people with non-squamous lung cancer that has certain high-risk features. The goal is to find the best next step to lower the chance of the cancer coming back, based on the type of gene change in the tumor.
This trial tests the targeted therapy drug ensartinib given after surgery to prevent lung cancer from coming back. It is only for people whose tumor has an ALK gene change and who are in early to moderately advanced stages after complete removal.
This trial tests an oral targeted therapy (Ensartinib) after surgery for patients with stage I ALK-positive lung cancer who have certain high-risk features. The goal is to see if it helps prevent cancer from returning.
Hear when a new Adjuvant Therapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.